Two Very Different Approaches to Ketamine Therapy
When people think of ketamine treatment, they often picture intravenous infusion — a clinic setting, an IV drip, a monitored recliner. Ketamine troches represent a fundamentally different model: home-based, oral administration with a simpler logistical footprint but different pharmacological characteristics. Neither approach is universally superior. The best choice depends on the patient's condition, goals, access to services, financial situation, and clinical history. For a detailed price breakdown, see our troches vs. IV cost comparison.
Bioavailability: The Fundamental Pharmacological Difference
IV Ketamine: 100% Bioavailability
Intravenous administration delivers ketamine directly into the bloodstream. Every milligram prescribed is delivered — nothing is lost to poor absorption, first-pass metabolism, or dissolution inefficiency. This means doses can be precisely controlled and plasma concentrations are highly predictable.
Typical IV infusion doses for treatment-resistant depression: 0.5 mg/kg administered over 40 minutes. For a 70 kg person, that's 35 mg of ketamine delivered with complete certainty into the bloodstream.
Ketamine Troches: 20-30% Bioavailability
Sublingual or buccal absorption delivers approximately 20 to 30 percent of the administered dose to systemic circulation. The rest is either absorbed from the gastrointestinal tract after swallowing (at lower efficiency due to first-pass metabolism) or lost entirely. This means a 200 mg troche delivers roughly 40 to 60 mg of effective systemic ketamine — similar in absolute terms to a 35 mg IV dose, but with considerably more variability.
Troche bioavailability varies significantly between patients and even between sessions in the same patient, depending on technique, salivary pH, mucosal blood flow, and other factors.
Clinical Implications
IV ketamine's precision allows for more reproducible plasma concentrations. Troche variability means the actual clinical dose delivered may differ meaningfully from session to session. For research purposes and for patients requiring very precise dosing, IV is the more reliable vehicle.
Efficacy: What the Research Shows
IV Ketamine Evidence
IV ketamine has the strongest evidence base for rapid antidepressant effects in treatment-resistant depression (TRD). The landmark studies by Zarate et al. (2006) and many subsequent trials use IV administration. Response rates of 50 to 70 percent for depressive symptoms within 24 hours have been reported, with many patients showing meaningful improvement after a single infusion.
IV ketamine also has robust evidence for rapid antisuicidal effects, which has made it a consideration in crisis settings.
Troche Efficacy Evidence
Evidence for sublingual ketamine is growing but remains less extensive than for IV. Key studies include work by Andrade (2017) and clinical data from outpatient practices, showing antidepressant effects comparable to lower-dose IV protocols in many patients. The critical distinction: with troches, the dose must be calibrated to account for bioavailability, meaning the appropriate comparison is not 200 mg troche vs. 0.5 mg/kg IV — the comparison must use equivalent estimated systemic doses.
For maintenance therapy specifically, oral and sublingual routes have practical advantages that have led many clinicians to use them after an initial acute course (often IV), with troches providing longer-term maintenance.
Cost Comparison
IV Ketamine Cost
A single IV ketamine infusion in the United States typically costs between $400 and $800 at a dedicated ketamine clinic. Standard acute treatment protocols involve 6 infusions over 2 to 3 weeks. Total acute course cost: $2,400 to $4,800.
Maintenance infusions (typically monthly) add $400 to $800 per session for ongoing care.
Insurance rarely covers IV ketamine for psychiatric indications.
Troche Cost
Compounded ketamine troches typically cost $150 to $400 per month for a maintenance course (2 to 4 sessions per month), depending on dose, quantity, and pharmacy. The prescribing provider visit fees (initial consultation plus monthly or bimonthly follow-ups) typically add another $100 to $300 per month for telemedicine providers.
Total monthly cost for troche therapy: roughly $250 to $700 per month.
Over 12 months, troche therapy often costs significantly less than ongoing IV infusion, though the acute treatment cost of a standard 6-infusion IV course may be comparable to several months of troche therapy.
Setting and Logistics
IV Ketamine: Clinic-Based
IV infusions must occur in a clinical setting with trained staff and monitoring equipment. This means:
- Scheduling around clinic hours
- Travel to and from the clinic (often requiring a driver)
- Time in the clinic (each session takes 1 to 2 hours including setup, infusion, and recovery)
- A significant time commitment: 6+ sessions over 2 to 3 weeks for the acute course
For patients in rural areas or with mobility limitations, clinic-based IV therapy may be inaccessible.
Troches: Home-Based
Troches can be used at home, on the patient's schedule. This means:
- No travel required
- Sessions can be scheduled on days and at times that suit the patient
- Significant logistics reduction
- Greater autonomy, which some patients find therapeutically beneficial
The tradeoff is reduced professional monitoring during sessions, placing more responsibility on the patient to maintain safety protocols.
Monitoring and Safety
IV Ketamine: Monitored
During IV infusions, patients are monitored for:
- Blood pressure and heart rate (typically measured every 5 to 10 minutes during infusion)
- Oxygen saturation
- Level of consciousness
- Acute psychiatric response
Clinical staff are present throughout and trained to manage adverse events. This monitoring is a meaningful safety advantage.
Troches: Self-Monitored
At-home troche sessions rely on the patient and any support person to manage safety. This means:
- No continuous vital sign monitoring (though home BP monitors are commonly recommended)
- No immediate clinical intervention available if significant adverse effects occur
- Safety depends on patient preparation, support person presence, and clear emergency protocols
Patients with significant cardiovascular risk, history of adverse reactions to dissociatives, or significant psychiatric instability may be better served by clinic-based treatment.
Patient Experience
IV Ketamine
Many patients describe IV ketamine as more intense and faster-reaching than troches. The rapid IV delivery produces a sharper onset of dissociative effects. Some patients find the clinical environment reassuring; others find it cold and anxiety-provoking.
The clinic setting removes the patient from their familiar home environment, which can be either stabilizing or limiting depending on the patient's therapeutic goals.
Troches
The home environment and slower onset of troches are often experienced as gentler and more comfortable. Patients can customize their set and setting more completely — their own bed, their own music, their own pillow. For patients who find the clinical environment anxiety-inducing, home-based therapy may produce better outcomes despite lower bioavailability.
Which Is Right for You?
Consider IV ketamine if:
- You have severe, acute treatment-resistant depression requiring rapid, reliable response
- You have significant cardiovascular risk factors requiring professional monitoring
- You have a history of adverse reactions to ketamine requiring on-site management
- You have access to a quality IV ketamine clinic and can afford the cost
- You want to establish response quickly before potentially transitioning to maintenance troches
Consider troches if:
- You are seeking maintenance therapy after establishing response with IV
- Cost is a significant factor and your condition is not acutely severe
- You live far from IV ketamine clinics
- You have good executive function and self-monitoring capability
- You prefer the autonomy and comfort of home-based treatment
Key Takeaways
- IV ketamine offers 100% bioavailability and stronger evidence; troches offer convenience and lower cost.
- Acute treatment protocols favor IV; maintenance therapy is well-suited to troches.
- IV costs $400 to $800 per session; troches cost $150 to $400 per month total.
- IV is monitored; troches require patient self-management of safety.
- Many patients use IV for the acute course and switch to troches for ongoing maintenance.
References
- StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
- PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
- MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
- Healthcare.gov: Understanding Costs — Federal marketplace resource explaining insurance terminology and out-of-pocket healthcare costs
Share